Log in
Enquire now
‌

US Patent 11160796 Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer

Patent 11160796 was granted and assigned to Aragon Pharmaceuticals on November, 2021 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent
0

Patent attributes

Patent Applicant
Aragon Pharmaceuticals
Aragon Pharmaceuticals
0
Current Assignee
Aragon Pharmaceuticals
Aragon Pharmaceuticals
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
111607960
Patent Inventor Names
Arturo Molina0
Date of Patent
November 2, 2021
0
Patent Application Number
202005280
Date Filed
May 28, 2020
0
Patent Citations Received
‌
US Patent 11491149 Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
‌
US Patent RE49353 Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
Patent abstract

Described herein are methods of treating non-metastatic castrate-resistant prostate cancer using an approved drug product comprising apalutamide, enzalutamide or darolutamide. Also described here are drug products containing apalutamide enzalutamide or darolutamide, and methods of selling or offering for sale an anti-androgen drug product.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 11160796 Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us